{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:47:59Z","timestamp":1794368879916,"version":"4.9.0"},"reference-count":79,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/17474086.2021.1959315","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T02:58:16Z","timestamp":1626922696000},"page":"687-696","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":29,"title":["Avapritinib for Systemic Mastocytosis"],"prefix":"10.1080","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1409760"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10560"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146563"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.277897"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2020-136930","article-title":"Increased detection of KIT D816V mutation in peripheral blood samples from patients with indolent systemic mastocytosis (ISM) in the phase 2 pioneer study using a high sensitivity droplet digital (dd) PCR assay compared with next generation sequencing (NGS)","volume":"136","author":"George TI","year":"2020","unstructured":"George TI, Hoehn G, Lin H, et al. Increased detection of KIT D816V mutation in peripheral blood samples from patients with indolent systemic mastocytosis (ISM) in the phase 2 pioneer study using a high sensitivity droplet digital (dd) PCR assay compared with next generation sequencing (NGS). Blood. 2020;136:3004.","journal-title":"Blood"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12043"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217950"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1964-1"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12409"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.127"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12916"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2234"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205237"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14248"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30166-8"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000932"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23380"},{"issue":"3121","key":"e_1_3_4_21_1","article-title":"Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis","volume":"8","author":"Schwaab J","year":"2020","unstructured":"Schwaab J, Cabral Do O Hartmann N, Naumann N, et al. Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis. J Allergy Clin Immunol Pract. 2020;8(3121):3127.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2677"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0203"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2008.070061"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496448"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.190"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020628"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018026245"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30400-2"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00640"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.02.002"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13237"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000504842"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13592"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2018.04.011"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3816"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10711"},{"issue":"1009","key":"e_1_3_4_39_1","first-page":"16","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete S","year":"2015","unstructured":"Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126(1009):16. quiz 1050.","journal-title":"Blood"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.234"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513098"},{"issue":"356","key":"e_1_3_4_44_1","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann K","year":"2020","unstructured":"Hartmann K, Gotlib J, Akin C, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020;146(356):366.e4.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-458521"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12920"},{"issue":"1006","key":"e_1_3_4_48_1","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"Van Anrooij B","year":"2018","unstructured":"Van Anrooij B, JNG OE, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial. J Allergy Clin Immunol. 2018;142(1006):1008.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.018"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2018"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1690"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0450-8"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16092"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3139"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01275-2"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0487"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00274"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137413"},{"key":"e_1_3_4_59_1","first-page":"2","article-title":"Clinical activity in a phase 1 study of blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM)","volume":"130","author":"DeAngelo DJ","year":"2017","unstructured":"DeAngelo DJ, Quiery AT, Radia D, et al. Clinical activity in a phase 1 study of blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM). Blood. 2017;130:2.","journal-title":"Blood"},{"key":"e_1_3_4_60_1","first-page":"3(S1):S830","article-title":"Avapritinib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (AdvSM)","author":"Radia D","year":"2019","unstructured":"Radia D, Deininger M, Gotlib J, et al. Avapritinib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (AdvSM). Hemasphere. 2019;3(S1):S830.","journal-title":"Hemasphere"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062983"},{"key":"e_1_3_4_62_1","first-page":"1079","article-title":"Avapritinib induces responses in patients with advanced systemic mastocytosis (advsm), regardless of prior midostaurin therapy","volume":"4","author":"Gotlib J","year":"2020","unstructured":"Gotlib J, Radia DH, George TI, et al. Avapritinib induces responses in patients with advanced systemic mastocytosis (advsm), regardless of prior midostaurin therapy. Hemasphere. 2020;4:1079.","journal-title":"Hemasphere"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764423"},{"key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-99-112017","article-title":"Avapritinib, a potent and selective inhibitor of KIT D816V, improves symptoms of advanced systemic mastocytosis (AdvSM): analyses of patient reported outcomes (PROs) from the phase 1 (EXPLORER) study using the (AdvSM) symptom assessment form (AdvSM-SAF), a new PRO questionnaire for (AdvSM)","volume":"132","author":"Gotlib JR","year":"2018","unstructured":"Gotlib JR, Radia D, DeAngelo DJ, et al. Avapritinib, a potent and selective inhibitor of KIT D816V, improves symptoms of advanced systemic mastocytosis (AdvSM): analyses of patient reported outcomes (PROs) from the phase 1 (EXPLORER) study using the (AdvSM) symptom assessment form (AdvSM-SAF), a new PRO questionnaire for (AdvSM). Blood. 2018;132:351.","journal-title":"Blood"},{"key":"e_1_3_4_65_1","first-page":"023","article-title":"PATHFINDER: interim analysis of avapritinib in patients with advanced systemic mastocytosis (AdvSM)","author":"DeAngelo DJ","year":"2021","unstructured":"DeAngelo DJ, Reiter A, Radia DH. et al. PATHFINDER: interim analysis of avapritinib in patients with advanced systemic mastocytosis (AdvSM). Cancer Res (AACR Annual Meeting Abstracts) 2021; 023.","journal-title":"Cancer Res (AACR Annual Meeting Abstracts)"},{"key":"e_1_3_4_66_1","first-page":"S201","article-title":"EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY","volume":"5","author":"Reiter A","year":"2021","unstructured":"Reiter A, DeAngelo DJ, Radia DH, et al. EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY. Hemasphere. 2021;5:S201.","journal-title":"Hemasphere"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136632"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30269-2"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1837109"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137480"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0366"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1988-0"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31403-9"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007258"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4617"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000152"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21013"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903470869"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.040"},{"key":"e_1_3_4_80_1","first-page":"122","article-title":"Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers","author":"Dave N","year":"2021","unstructured":"Dave N, Devlin M, Rodstrom J. et al. Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers. Cancer Res (AACR Annual Meeting Abstracts). 2021; 122.","journal-title":"Cancer Res (AACR Annual Meeting Abstracts)"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01348-2"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2021.1959315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:17:24Z","timestamp":1742379444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2021.1959315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/17474086.2021.1959315"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2021.1959315","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}